Symbols

SRZN

Surrozen·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 1

Consensus Rating "Buy"

Ample Liquidity

High Gross Profit Margin

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About SRZN

Surrozen, Inc.

A company that pioneered targeted therapeutics for tissue repair and regeneration

Industry

Pharmaceutical

Established Date

08/21/2020

Listing Date

08/12/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.surrozen.com

Security Type

Common stock

Office address

171 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080

Business

Introduction

Surrozen, Inc., a biotechnology company incorporated in Delaware on August 21, 2020. The company is committed to discovering and developing product candidates that selectively modulate the Wnt pathway (a key mediator for tissue repair), with a current strategic focus on the ophthalmology field, where Wnt signaling plays a central role in retinal vascular integrity, barrier function and tissue maintenance. Based on the pioneering work of its founders and scientific advisors in discovering the Wnt gene and its key regulators, Surrozen has made a breakthrough discovery that enables the rapid and flexible design of tissue-targeted therapies that modulate Wnt signaling. These findings form the basis of its ophthalmic product portfolio and research projects aimed at restoring tissue structure and function for serious ophthalmic diseases with unmet medical needs. Its main product candidate is an antibody-based multispecific biological agent that mimics the function of natural Wnt proteins.

Company Financials

EPS

SRZN has released its 2025 Q4 earnings. EPS was reported at -20.09, versus the expected -1.03, missing expectations. The chart below visualizes how SRZN has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

SRZN has released its 2025 Q4 earnings report, with revenue of 528.00K, reflecting a YoY change of -19.39%, and net profit of -183.16M, showing a YoY change of -553.23%. The Sankey diagram below clearly presents SRZN's revenue sources and cost distribution.